Drug intelligence / Profile preview

LNP-GF CAR mRNA

Development stage: Preclinical
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

LNP-GF CAR mRNA is a therapeutic modality that uses lipid nanoparticles (LNPs) to deliver messenger RNA (mRNA) encoding chimeric antigen receptors (CARs) to T cells. This approach aims to reprogram T cells in vivo to express CARs that target specific cancer antigens, potentially offering a more accessible alternative to conventional CAR T cell therapy which requires complex ex vivo manufacturing processes. The technology combines the targeted delivery capabilities of LNPs with the genetic instructions provided by mRNA to create CAR-expressing T cells capable of recognizing and eliminating cancer cells.

Targets

γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on LNP-GF CAR mRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNP-GF CAR mRNA.

Explore the full profile